Aspire2B Personalization Pilot Study Program
Launched by PEPSICO GLOBAL R&D · Jan 2, 2024
Trial Information
Current as of November 02, 2025
Recruiting
Keywords
ClinConnect Summary
The Aspire2B Personalization Pilot Study Program is a research project aimed at exploring how well the Aspire2B mobile app works for improving behaviors and lifestyles related to health. This study is currently looking for participants, and anyone between the ages of 65 to 74 or 27 to 39 who uses a smartphone and can read English or Spanish may be eligible to join.
If you decide to participate, you'll need to download the Aspire2B app, agree to its terms of use, and give your consent. There are no random assignments in this study; instead, it focuses on understanding how users interact with the app. By participating, you’ll help researchers learn more about how to make the app better for everyone. This is a great opportunity to contribute to the development of a tool that could help many people improve their health and lifestyle choices.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Fluent in reading and understanding English or Spanish
- • Smartphone users
- Exclusion Criteria:
- • Cannot proceed to onboarding without downloading the app, consenting to participate, and agreeing to app Terms of Use
About Pepsico Global R&D
PepsiCo Global R&D is a leading innovator in the food and beverage industry, dedicated to advancing the science of nutrition and product development. With a strong focus on health and wellness, the organization conducts rigorous clinical trials to explore the efficacy and safety of its products, aiming to enhance consumer experiences while promoting sustainable practices. Leveraging cutting-edge research methodologies and a multidisciplinary approach, PepsiCo Global R&D collaborates with academic institutions and healthcare professionals to drive evidence-based advancements in nutrition, ensuring that its offerings meet the evolving needs of consumers worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Tristin Brisbois, PhD, MBS
Principal Investigator
PepsiCo Global R&D
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported